We are live on ! Find out more
PA

Perceptive Advisors Portfolio holdings

AUM $5.12B
1-Year Est. Return 314.02%
This Fund
S&P 500
This Quarter Est. Return
+65.27%
1 Year Est. Return
+314.02%
3 Year Est. Return
+1,498.66%
5 Year Est. Return
+2,457.67%
10 Year Est. Return
+48,821.41%
AUM
$5.03B
AUM Growth
+$1.32B
Cap. Flow
-$125M
Cap. Flow %
-2.48%
Top 10 Hldgs %
53.64%
Holding
139
New
31
Increased
25
Reduced
19
Closed
25

Top Buys

Rank Stock Value
1
KRRO icon
Korro Bio
KRRO
+$47.2M
2
AGIO icon
Agios Pharmaceuticals
AGIO
+$34M
3
ANAB icon
AnaptysBio
ANAB
+$23.6M
4
QTNT
Quotient Limited Ordinary Shares
QTNT
+$20.7M
5
ZGNX
Zogenix, Inc.
ZGNX
+$20.4M

Top Sells

Rank Stock Value
1
DOVA
Dova Pharmaceuticals, Inc. Common Stock
DOVA
+$104M
2
SLDB icon
Solid Biosciences
SLDB
+$69.8M
3
NBIX icon
Neurocrine Biosciences
NBIX
+$46.8M
4
IOVA icon
Iovance Biotherapeutics
IOVA
+$36.4M
5
ONCE
Spark Therapeutics, Inc. Common Stock
ONCE
+$33.9M

Sector Composition

Rank Sector Weight
1 Healthcare 95.17%
2 Financials 0.38%
3 Technology 0.12%
4 Consumer Discretionary 0.04%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
ADMA icon
26
ADMA Biologics
ADMA
$2.02B
$46.1M 0.92%
11,521,102
– –
PRVB
27
DELISTED
Provention Bio, Inc. Common Stock
PRVB
$43.5M 0.86%
2,921,574
+2,255,252
+338% +$20.1M
ALBO
28
DELISTED
Albireo Pharma Inc
ALBO
$43.3M 0.86%
1,704,330
– –
ARNA
29
DELISTED
Arena Pharmaceuticals Inc
ARNA
$43.3M 0.86%
953,129
– –
AGIO icon
30
Agios Pharmaceuticals
AGIO
$2.08B
$43M 0.85%
+900,000
New +$34M
TVTX icon
31
Travere Therapeutics
TVTX
$5.17B
$41M 0.82%
2,890,608
-379,963
-12% -$4.85M
ALLO icon
32
Allogene Therapeutics
ALLO
$625M
$40.1M 0.8%
1,543,790
– –
EIDX
33
DELISTED
Eidos Therapeutics, Inc. Common Stock
EIDX
$40M 0.8%
697,524
+10,532
+2% +$521K
UROV
34
DELISTED
Urovant Sciences Ltd.
UROV
$37.3M 0.74%
2,406,931
+160,384
+7% +$1.74M
FOMX
35
DELISTED
Foamix Pharmaceuticals Ltd. Ordinary Shares
FOMX
$37.3M 0.74%
11,203,881
– –
NEPT
36
DELISTED
Neptune Wellness Solutions Inc. Ordinary Shares
NEPT
$36.8M 0.73%
9,598
– –
MTEM
37
DELISTED
Molecular Templates, Inc.
MTEM
$34.6M 0.69%
164,942
+33,333
+25% +$4.79M
AGRX
38
DELISTED
Agile Therapeutics
AGRX
$29.8M 0.59%
5,960
+597
+11% +$2.08M
ESTA icon
39
Establishment Labs
ESTA
$2.71B
$29.1M 0.58%
1,050,528
-210,000
-17% -$4.65M
ITCI
40
CALL
DELISTED
Intra-Cellular Therapies Inc.
ITCI
$28.6M 0.57%
+800,600
New +$9.61M
TPTX
41
DELISTED
Turning Point Therapeutics, Inc. Common Stock
TPTX
$27.2M 0.54%
437,390
-159,800
-27% -$7.6M
CTMX icon
42
CytomX Therapeutics
CTMX
$690M
$27M 0.54%
3,253,923
– –
BIO icon
43
Bio-Rad Laboratories Class A
BIO
$8.76B
$25.3M 0.5%
68,489
+3,489
+5% +$1.23M
RGNX icon
44
Regenxbio
RGNX
$616M
$24.9M 0.49%
608,000
– –
VAPO
45
DELISTED
Vapotherm, Inc. Common Stock
VAPO
$21.2M 0.42%
217,971
-2,588
-1% -$218K
CNCE
46
DELISTED
Concert Pharmaceuticals, Inc.
CNCE
$19.8M 0.39%
2,150,641
-44,000
-2% -$312K
STOK icon
47
Stoke Therapeutics
STOK
$1.84B
$19M 0.38%
671,978
– –
EHTH icon
48
eHealth
EHTH
$41.9M
$19M 0.38%
197,720
-57,369
-22% -$4.45M
TNDM icon
49
Tandem Diabetes Care
TNDM
$1.27B
$18.5M 0.37%
310,000
+303,578
+4,727% +$18.7M
ALDX icon
50
Aldeyra Therapeutics
ALDX
$97.1M
$17.9M 0.36%
3,085,458
– –
1
2
3 4 5

Similar funds

BG
Baupost Group Boston, Massachusetts $5.12B AUM 15.99% 1-Year Est. Return
TAM
Todd Asset Management Louisville, Kentucky $5.11B AUM 34.73% 1-Year Est. Return
CIA
Choate Investment Advisors Boston, Massachusetts $5.11B AUM 17.2% 1-Year Est. Return
AC
AKO Capital London, United Kingdom $5.11B AUM 2.56% 1-Year Est. Return
EIC
Equity Investment Corp Atlanta, Georgia $5.11B AUM 8.63% 1-Year Est. Return
CIC
Carnegie Investment Counsel Pepper Pike, Ohio $5.13B AUM 22.98% 1-Year Est. Return
CS
Cannell & Spears New York $5.1B AUM 31.77% 1-Year Est. Return
NC
Nicholas Company Milwaukee, Wisconsin $5.1B AUM 8.43% 1-Year Est. Return

Perceptive Advisors's Q4 2019 Portfolio in Review

As of Q4 2019, Perceptive Advisors held 139 positions worth $5.03B, up 36% from $3.71B the previous quarter. Its ten largest holdings account for 54% of the portfolio.

Perceptive Advisors's Q4 2019 filing shows 31 new, 25 increased, 19 reduced and 25 closed positions. Its largest new stake was Korro Bio: 60,686 shares worth $49.8M. The largest sale was Dova Pharmaceuticals, Inc. Common Stock, an estimated $104M.

By sector, the portfolio is most concentrated in Healthcare at 95% of assets, up from 94% a quarter earlier, followed by Financials and Technology.

  • Perceptive Advisors's largest Q4 2019 buy was Korro Bio: 60,686 shares worth $49.8M.
  • Perceptive Advisors added most to Quotient Limited Ordinary Shares in Q4 2019, an estimated $20.7M increase.
  • Perceptive Advisors's biggest Q4 2019 reduction was Neurocrine Biosciences, cutting an estimated $46.8M.
  • Perceptive Advisors fully exited Dova Pharmaceuticals, Inc. Common Stock in Q4 2019, selling an estimated $104M.
  • Perceptive Advisors's ten largest holdings make up 54% of its $5.03B portfolio in Q4 2019.
  • Perceptive Advisors opened 31 new positions and closed 25 in Q4 2019.
  • Perceptive Advisors's portfolio value rose 36% quarter-over-quarter to $5.03B.

Based on Perceptive Advisors's 13F filing for Q4 2019, filed 14 Feb 2020.